Recognan - Instructions For Use, Price, Reviews, Analogs, Solution 1000 Mg

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Recognan

Recognan: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. Use in childhood
11. 11. Use in the elderly
12. 12. Drug interactions
13. 13. Analogs
14. 14. Terms and conditions of storage
15. 15. Terms of dispensing from pharmacies
16. 16. Reviews
17. 17. Price in pharmacies

Latin name: Recognan

ATX code: N06BX06

Active ingredient: citicoline (citicoline)

Producer: Moscow Endocrine Plant (Russia), Alfa Wassermann (Italy)

Description and photo updated: 2018-21-11

Prices in pharmacies: from 319 rubles.

Buy

Recognan is a nootropic and neuroprotective agent.

Release form and composition

Dosage forms of Recognan:

• oral solution: colorless transparent liquid with a characteristic strawberry odor (30 ml each in transparent glass bottles, sealed with a screw cap with first opening control, in a cardboard box 1 bottle with a dosing pipette; 10 ml each in sachets made of multilayer combined material, in cardboard box 5 or 10 sachets);
• solution for intravenous (i / v) and intramuscular (i / m) administration: colorless transparent liquid (4 ml each in colorless glass ampoules with a precise or break line, in a blister strip packaging 5 ampoules, in a cardboard box 1 or 2 contour packs) …

Composition of 1 ml of oral solution:

• active substance: citicoline monosodium salt - 1045 mg, which corresponds to the content of citicoline - 100 mg;
• auxiliary components: methyl parahydroxybenzoate, sodium saccharinate, glycerol, sorbitol, potassium sorbate, propyl parahydroxybenzoate, sodium citrate dihydrate, citric acid, purified water, strawberry flavor FRESA S. 1487S.

Composition of 1 ampoule of solution for intravenous and intramuscular administration:

• active substance: citicoline monosodium salt - 522.5 or 1045 mg, which is equivalent to 500 and 1000 mg of citicoline, respectively;
• additional components: water for injection, sodium hydroxide or hydrochloric acid.

Pharmacological properties

Pharmacodynamics

The active ingredient of Recognan is citicoline, a precursor of key ultrastructural components of the cell membrane (mainly phospholipids), which has a wide spectrum of action: it prevents the excessive formation of free radicals, inhibits the action of phospholipases, restores damaged cell membranes, and also affects the mechanisms of apoptosis, thereby preventing cell death.

After traumatic brain injury, the drug reduces the severity of neurological symptoms, the duration of post-traumatic coma and the duration of the recovery period.

In the acute period of stroke, Recognan reduces the amount of damage to the brain tissue and improves cholinergic transmission.

In chronic cerebral ischemia, citicoline eliminates disorders such as lack of initiative, memory impairment, difficulty in self-care and in performing daily activities. Reduces manifestations of amnesia, increases attention and level of consciousness.

Citicoline is effective in sensory, motor neurological and cognitive disorders of degenerative and vascular etiology.

Pharmacokinetics

After taking Recognan inside, citicoline is rapidly and almost completely absorbed. Oral bioavailability is approximately the same as intravenous administration. It is metabolized in the intestine and liver.

With i / v and i / m administration of the drug, citicoline is metabolized only in the liver.

As a result of metabolism, the main metabolites cytidine and choline are formed. The use of Recognan contributes to a significant increase in the level of choline in the blood plasma.

Citicoline is largely distributed in the structures of the brain, as a result of which cytidine fractions are rapidly incorporated into cytidine nucleotides and nucleic acids, choline fractions - into structural phospholipids. Penetrating into the brain, the drug is actively incorporated into mitochondrial, cellular and cytoplasmic membranes, forming fractions of structural phospholipids.

Only 15% of the received dose of Recognan is excreted from the human body. Of these, about 12% is excreted with exhaled air, no more than 3% through the intestines and kidneys.

In the excretion of citicoline by the kidneys with urine, two phases are distinguished: during the first phase, which lasts about 36 hours, the rate of excretion decreases rapidly, during the second excretion decreases much more slowly. A similar phasicity is observed in the exhaled air: after about 15 hours, the rate of excretion decreases rapidly, and later on, much more slowly.

Indications for use

• cognitive and behavioral disorders in vascular and degenerative diseases of the brain;
• craniocerebral trauma, acute (as part of complex therapy) and recovery periods;
• acute period of ischemic stroke (as part of complex therapy);
• recovery periods of hemorrhagic and ischemic strokes.

Contraindications

• the predominance of the tone of the parasympathetic part of the autonomic nervous system (pronounced vagotonia);
• age up to 18 years;
• lactation period;
• rare hereditary diseases associated with fructose intolerance (oral solution);
• hypersensitivity to any component of Recognan.

Instructions for the use of Recognan: method and dosage

Oral solution

Recognan should be taken with meals or between meals. Immediately before taking, the solution can be diluted in a small amount of water (½ cup).

In the acute period of traumatic brain injury and ischemic stroke, the recommended dose is 1000 mg of Recognan 2 times a day (at intervals of 12 hours) for at least 6 weeks.

In the recovery period after traumatic brain injury, ischemic and hemorrhagic strokes, with vascular and degenerative diseases of the brain, 500-2000 mg per day are prescribed, depending on the severity of the symptoms of the disease. The duration of treatment is determined individually.

When calculating the required dose, it should be borne in mind that 1 ml of solution contains 100 mg of citicoline, 1 sachet - 1000 mg, 1 bottle - 3000 mg.

Instructions for use of the drug Recognan in vials:

1. Place the supplied dosing pipette into the bottle (the plunger must be fully lowered).
2. Pull gently on the plunger and pipette the solution up to the required mark.
3. If necessary, dilute the drug in water (approximately 120 ml).
4. Rinse the pipette with clean water.

Recommendations for the use of the drug Recognan in sachets:

1. Take the bag by the edge and shake well.
2. Tear off the edge of the bag along the dotted line.
3. Drink the contents of the package. If necessary, you can first dissolve it in ½ glass of water.

Injection

Recognan can be administered intramuscularly, intravenously (40-60 drops per minute) or as a slow injection (within 3-5 minutes). The intravenous route of administration is preferred.

In the acute period of traumatic brain injury and ischemic stroke, the recommended dose is 1000 mg of Recognan 2 times a day (at intervals of 12 hours) for at least 6 weeks. 3-5 days after the start of therapy, the patient can be transferred to the drug in the form of a solution for oral administration (if the swallowing function is not impaired).

In the recovery period after traumatic brain injury, ischemic and hemorrhagic strokes, with vascular and degenerative diseases of the brain, 500-2000 mg per day are prescribed, depending on the severity of the symptoms of the disease. The duration of treatment is determined individually.

Recognan is compatible with all types of intravenous dextrose solutions and isotonic solutions.

The ampoule should be opened immediately before administration. It is recommended not to inject the drug in the same place, but to change the injection site.

Side effects

Recognan is generally well tolerated. Very rarely (<1/10000, including individual cases) causes the following side effects:

• headache, dizziness, insomnia, hallucinations, agitation, tremors;
• decreased appetite, diarrhea, nausea, vomiting, changes in the activity of liver enzymes;
• numbness in paralyzed limbs;
• dyspnea;
• swelling;
• feeling hot;
• allergic reactions (itching, skin rashes, anaphylactic shock);
• stimulation of the parasympathetic system;
• short-term change in blood pressure.

Overdose

Overdose has not been reported. Recognan is characterized by low toxicity, so overdose is unlikely.

special instructions

In a solution for oral administration in the cold, a small amount of crystals may form. They dissolve within several months upon further storage at room temperature and do not affect the quality and effectiveness of the drug.

Influence on the ability to drive vehicles and complex mechanisms

Drivers of vehicles, operators, dispatchers and persons of other professions, whose activities are related to the performance of work requiring increased attention and speed of psychophysical reactions, should be careful during treatment.

Application during pregnancy and lactation

In animal studies, no adverse effects on the fetus have been identified, however, the available data are insufficient to assess the safety of citicoline in pregnant women. Therefore, during pregnancy, Recognan is prescribed only if the intended benefits of therapy are higher than the potential risks.

If treatment is required during lactation, breastfeeding is recommended to be discontinued, since it has not been established whether citicoline is excreted in mother's milk.

Childhood use

According to the instructions, Recognan is not used under the age of 18.

Use in the elderly

No dose adjustment is required in elderly patients.

Drug interactions

Recognan should not be used in combination with medicinal products that include meclofenoxate.

With the simultaneous use of levodopa, its effect is enhanced.

Analogs

Analogues of Recognan are the drugs Neipilept and Ceraxon.

Terms and conditions of storage

Keep out of the reach of children at a temperature: oral solution - 15-25 ° С, injection solution - up to 25 ° С.

The shelf life of the oral solution is 2 years, the solution for injection is 3 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Recognan

Few reviews of Recognan testify to its effectiveness. The drug eliminates cognitive disorders, reduces the severity of neurological symptoms, has practically no contraindications and is well tolerated.

The price of Recognan in pharmacies

Approximate prices for Recognan:

• oral solution - 378–458 rubles. per bottle of 30 ml, 1115-1285 rubles. for 10 sachets of 10 ml;
• solution for intravenous and intramuscular administration at a dose of 500 mg / 4 ml - 463–554 rubles. for 5 ampoules;
• solution for intravenous and intramuscular administration at a dose of 1000 mg / 4 ml - 798-910 rubles. for 5 ampoules.

Recognan: prices in online pharmacies

Drug name Price Pharmacy

Recognan 500 mg / 4 ml solution for intravenous and intramuscular administration 4 ml 5 pcs. RUB 319 Buy

Recognan 100 mg / ml oral solution 30 ml 1 pc. 367 r Buy

Recognized solution for internal approx. 100mg / ml vial with 30ml 376 r Buy

Recognized solution for intravenous and intramuscular injection. 500mg / 4ml amp. 4ml 5 pcs 543 r Buy

Recognan 1000 mg / 4 ml solution for intravenous and intramuscular administration 4 ml 5 pcs. 591 r Buy

Recognized solution for intravenous and intramuscular injection. 1000mg / 4ml amp. 4ml 5 pcs 922 RUB Buy

Recognan 100 mg / ml oral solution 10 ml 10 pcs. 939 RUB Buy

Maria Kulkes Medical journalist About the author

Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes and does not replace the official instructions. Self-medication is hazardous to health!